Inventprise is an innovative vaccine development company based out of Redmond, Washington that is focused on developing efficacious, affordable vaccines for global populations most in need. The foundation invested in the Company to advance its novel pneumococcal conjugate vaccine (“IVT-25”). Read More
The foundation invested in Liquidia to support the application of Liquidia’s PRINT® technology to vaccine development for infectious diseases.
Affinivax achieves unprecedented levels of immune response and disease protection by streamlining the process of vaccine design and allowing for multiple antigens to be effectively incorporated in a single vaccine.
By Ben Fidler October 30, 2014 Prevnar 13 is a vaccine that, as its name suggests, protects against 13 of the most common strains of pneumococcal bacteria, which can cause deadly pneumonia and meningitis infections. There’s just one problem: there Read More